Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

OP used HIMS hybrid tablets containing 1.1mg finasteride, 3mg minoxidil, and 2.5mg biotin, showing significant hair regrowth after initial shedding. OP experienced no side effects and plans to continue treatment.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

A user shared their positive 3-month hair regrowth results using a 3-in-1 pill containing finasteride, minoxidil, and biotin, with no side effects. They also started microneedling, Nizoral, and caffeine shampoo to enhance growth.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

Everychem's solution, similar to PP405, has mixed results for hair regrowth, with some users reporting improvements and others seeing no change or worsening hair loss. Users are sharing experiences and updates to determine its effectiveness.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

Significant hair regrowth was achieved using RU58841, minoxidil, and microneedling during a high-dose steroid cycle. The user reported no side effects from RU58841 and plans to continue the regimen.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

CB-03-01, also known as Breezula, is being considered as an alternative to DHT blockers for hair loss. Users are discussing its effectiveness, potential regrowth, side effects like scalp irritation, and hormonal impacts.

JXL069, also known as PP405, did not lead to hair regrowth after a year of testing. The lack of results may be due to formulation issues, leading to a final attempt with an improved vehicle.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

A person had a successful hair transplant in Turkey with 3200 grafts using FUE and DHI techniques, and is satisfied with the results after 9 months. They have been using finasteride for 7 years to maintain hair health.

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.

A user is considering a 3-in-1 capsule containing Finasteride, Minoxidil, and Biotin for hair loss. Concerns are raised about Biotin's impact on the effectiveness of Finasteride and Minoxidil, and the cost is unclear without logging in.

People are pessimistic about PP405, believed to be Jxl-069, due to doubts about its effectiveness and delivery method. Some think it doesn't work, while others blame the vehicle used for application.

The user reported hair thickening and new growth after using minoxidil and microneedling for over three months. They are considering finasteride but have not started it yet.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

A user shared their 3-month hair growth progress using 1mg oral finasteride, 5% topical minoxidil, and microneedling with a 1.5 mm dermaroller twice weekly. The user received positive feedback and expressed a desire for thicker hair in the future.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

A user shared impressive hair regrowth results after 4 months using topical minoxidil, oral finasteride, and 3 PRP sessions. They plan to continue with these treatments and add dermastamping.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The user has been using 1 mg finasteride daily for 3 months, with recent additions of 2.5 mg oral minoxidil and microneedling, and is seeing some hair regrowth. They are seeking opinions on their progress and discussing treatment options with others.

The conversation discusses the availability and legitimacy of a hair loss treatment called PP405-3HP. Users express skepticism about its release and reference patent information.

A 24-year-old shares progress on hair regrowth after 3 months using 2.5mg oral minoxidil, 0.5mg dutasteride, and scalp injections of dutasteride, minoxidil, and vitamins every two weeks. They are uncertain if the improvement is due to actual regrowth or just longer hair.